Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Neurological Medicine
Volume 2017 (2017), Article ID 1410759, 3 pages
https://doi.org/10.1155/2017/1410759
Case Report

Seizure following the Use of the COX-2 Inhibitor Etoricoxib

Dipartimento di Biomedicina Sperimentale e Neuroscienze Cliniche, Università degli Studi di Palermo, Palermo, Italy

Correspondence should be addressed to Paolo Aridon; ti.apinu@nodira.oloap

Received 23 August 2016; Revised 13 December 2016; Accepted 9 January 2017; Published 22 January 2017

Academic Editor: Mehmet Turgut

Copyright © 2017 Valentina Arnao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. E. Lipsky, P. Brooks, L. J. Crofford et al., “Unresolved issues in the role of cyclooxygenase-2 in normal physiologic processes and disease,” Archives of Internal Medicine, vol. 160, no. 7, pp. 913–920, 2000. View at Publisher · View at Google Scholar · View at Scopus
  2. M. A. Perazella and K. Tray, “Selective cyclooxygenase-2 inhibitors: a pattern of nephrotoxicity similar to traditional nonsteroidal anti-inflammatory drugs,” American Journal of Medicine, vol. 111, no. 1, pp. 64–67, 2001. View at Publisher · View at Google Scholar · View at Scopus
  3. R. A. Bonnel, M. L. Villalba, C. B. Karwoski, and J. Beitz, “Aseptic meningitis associated with rofecoxib,” Archives of Internal Medicine, vol. 162, no. 6, pp. 713–715, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. B. Mayer, R. Genth, R. Dehner, and A. Salama, “The first example of a patient with etoricoxib-induced immune hemolytic anemia,” Transfusion, vol. 53, no. 5, pp. 1033–1036, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. L. Thirion, A. F. Nikkels, and G. E. Piérard, “Etoricoxib-induced erythema-multiforme-like eruption,” Dermatology, vol. 216, no. 3, pp. 227–228, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Krumholz, S. Wiebe, S. Gary et al., “Evidence-based guideline: management of an unprovoked first seizure in adults,” Report of the Guideline Development Subcommittee of the American Academy of Neurology and the American Epilepsy Society, vol. 84, no. 16, pp. 1705–1713, 2015. View at Google Scholar
  7. J. Katyal, H. Kumar, and Y. K. Gupta, “Anticonvulsant activity of the cyclooxygenase-2 (COX-2) inhibitor etoricoxib in pentylenetetrazole-kindled rats is associated with memory impairment,” Epilepsy & Behavior, vol. 44, pp. 98–103, 2015. View at Publisher · View at Google Scholar · View at Scopus
  8. N. Delanty, C. J. Vaughan, and J. A. French, “Medical causes of seizures,” The Lancet, vol. 352, no. 9125, pp. 383–390, 1998. View at Publisher · View at Google Scholar · View at Scopus
  9. D. H. Lowenstein and B. K. Alldredge, “Status epilepticus at an urban public hospital in the 1980s,” Neurology, vol. 43, no. 3, pp. 483–488, 1993. View at Publisher · View at Google Scholar · View at Scopus
  10. G. R. Pesola and J. Avasarala, “Bupropion seizure proportion among new-onset generalized seizures and drug related seizures presenting to an emergency department,” Journal of Emergency Medicine, vol. 22, no. 3, pp. 235–239, 2002. View at Publisher · View at Google Scholar · View at Scopus
  11. H. Rantala, R. Tarkka, and M. Uhari, “Systematic review of the role of prostaglandins and their synthetase inhibitors with respect to febrile seizures,” Epilepsy Research, vol. 46, no. 3, pp. 251–257, 2001. View at Publisher · View at Google Scholar · View at Scopus
  12. T. Shimada, T. Takemiya, H. Sugiura, and K. Yamagata, “Role of inflammatory mediators in the pathogenesis of epilepsy,” Mediators of Inflammation, vol. 2014, Article ID 901902, 8 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. L. Gordi, Epidemiology, Elsevier, 5th edition, 2013.